



#4
BT
01-09-02

Attorney Docket No. ~~ISC~~ R007/00US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Neuman et al.

Serial No.: 09/774,791

Examiner: To be assigned

Confirmation No. 2627

Art Unit: 2166

Filed: February 1, 2001

For: **SYSTEM AND METHOD FOR CREATING PRESCRIPTIONS**

RECEIVED
AUG 13 2001
Technology Center 2100

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08 for the above-identified patent application.

- ☒ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ In accordance with 37 C.F.R. §1.97(c), also enclosed is:
 - ☐ the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
 - ☐ a statement as specified in 37 C.F.R. §1.97(e).
- ☐ In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ Check No. ___ in the amount of \$___ for the total fee is attached.
- ☐ Please charge \$___ to Deposit Account No. 50-1283 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-1283.


Dated: August 9, 2001

Cooley Godward LLP
ATTN: Patent Group
One Freedom Square
Reston Town Center
11951 Freedom Drive
Reston, VA 20190-5601
Tel: (703) 456-8000
Fax: (703) 456-8100

103920 v1/RE
286_01!.DOC

Respectfully submitted,
COOLEY GODWARD LLP

By:


Jeffrey A. Pade
Reg. No. 42,970



Attorney Docket No. 45CR003700US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
AUG 13 2001
Technology Center 2100

In re application of Neuman et al.

Serial No.: 09/774,791

Examiner: To be assigned

Confirmation No. 2627

Art Unit: 2166

Filed: February 1, 2001

For: **SYSTEM AND METHOD FOR CREATING PRESCRIPTIONS**

Commissioner for Patents
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.
§§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached
Form PTO/SB/08 is enclosed.

This Information Disclosure Statement is filed within any one of the following
time periods:

- ☐ within three months from the filing date of this national application
other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as
set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a
request for continued examination under 37 C.F.R. § 1.114.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

Dated: August 9, 2001

Cooley Godward LLP
ATTN: Patent Group
One Freedom Square
Reston Town Center
11951 Freedom Drive
Reston, VA 20190-5601
Tel: (703) 456-8000
Fax: (703) 456-8100


Respectfully submitted,
COOLEY GODWARD LLP

By:



Jeffrey A. Pade
Reg. No. 42,970

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			<i>Complete if Known</i>		
			Application Number	09/774,791	
			Filing Date	February 1, 2001	
			First Named Inventor	Neuman et al.	
			Group Art Unit	2166	
			Examiner Name	not assigned	
Sheet	2	of	2	Attorney Docket Number	ISCR007/00US

RECEIVED
 AUG 13 2001
 Technology Center 2100

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	C1	FRANCIS B. PALUMBO et al., "Drug Use Evaluation", Principals and Practices of Managed Care Pharmacy, Academy of Managed Care Pharmacy, 1999, Chapter 5, pp. 51-60	
	C2	RENEE T. KUBACKA, "A Primer on Drug Utilization Review", Journal of the American Pharmaceutical Association, 1996, Vol. NS36, No. 4, pp. 257-261 and 279	
	C3	WILLIAM N. YATES, JR. MS, et al., "A Drug Utilization Evaluation Primer: Conceptual and Operational Aspects", Group Health Association of America Annual Meeting, June 23-26, 1991	
	C4	APhA Special Report, "Opportunities for the Community Pharmacist in Managed Care", American Pharmaceutical Association, 1994	
	C5	American Society of Health Systems Pharmacists, "ASHP Statement on the Pharmacist's Clinical Role in Organized Health-Care Settings", American Journal of Hospital Pharmacy, 1989, Vol. 46, pp. 805-806	
	C6	LEE BOWMAN, "Drug Use Evaluation is DUE: Healthcare Utilization Evaluation is Over-DUE", Hospital Pharmacy, 1996, Vol. 31, No. 4, pp. 347-353	
	C7	Academy of Managed Care Pharmacy, "Concepts in Managed Care Pharmacy Series – Pharmaceutical Care" 1997	
	C8	Academy of Managed Care Pharmacy, "Concepts in Managed Care Pharmacy – Drug Use Evaluation" 1999	
	C9	The Joint Commission on Accreditation of Healthcare Organizations, "Comprehensive Accreditation Manual for Hospitals", 1995	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.